Hologic, Inc. (HOLX)

NASDAQ: HOLX · IEX Real-Time Price · USD
69.78
-1.68 (-2.35%)
At close: Jun 28, 2022 4:00 PM
69.80
+0.02 (0.03%)
After-hours: Jun 28, 2022 5:38 PM EDT
-2.35%
Market Cap 17.40B
Revenue (ttm) 5.39B
Net Income (ttm) 1.55B
Shares Out 249.38M
EPS (ttm) 6.06
PE Ratio 11.52
Forward PE 16.81
Dividend n/a
Ex-Dividend Date n/a
Volume 1,279,777
Open 71.99
Previous Close 71.46
Day's Range 69.70 - 72.27
52-Week Range 66.26 - 81.04
Beta 1.09
Analysts Buy
Price Target 81.09 (+16.2%)
Earnings Date Jul 27, 2022

About HOLX

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-... [Read more...]

Industry Health Care Equipment & Supplies
IPO Date Jun 21, 1990
CEO Stephen MacMillan
Employees 6,705
Stock Exchange NASDAQ
Ticker Symbol HOLX
Full Company Profile

Financial Performance

In 2021, Hologic's revenue was $5.63 billion, an increase of 49.14% compared to the previous year's $3.78 billion. Earnings were $1.87 billion, an increase of 67.82%.

Financial Statements

Analyst Forecast

According to 22 analysts, the average rating for HOLX stock is "Buy." The 12-month stock price forecast is 81.09, which is an increase of 16.21% from the latest price.

Price Target
$81.09
(16.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Is Most-Watched Stock Hologic, Inc. (HOLX) Worth Betting on Now?

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Hologic (HOLX) New Products Aid Growth, Margin Pressure Stays

Hologic's (HOLX) core molecular diagnostics franchise is growing driven by strong uptake in newer assays such as vaginitis panel and menu within the virology product line.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Why Is Hologic (HOLX) Up 6.7% Since Last Earnings Report?

Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?

Hologic (HOLX) Gets CE Mark for Fusion Molecular Assays

Hologic's (HOLX) two new molecular assays monitor transplant patients for EBV and BKV.

Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #EpsteinBarr--Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients

Stocks This Week: Buy Hologic And Paychex

Stocks are likely to rally, and this pair of equities are likely to lead.

Other symbols: PAYX

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

Investors are optimistic about Hologic's (HOLX) better-than-expected results and robust segmental growth.

Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #NACD--Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree

Final Trades: Charles Schwab, Merck, Hologic & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: MRKSCHWWBA

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #Aptima--Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) approved its Aptima CMV Quant assay to quantify the viral loa...

Hologic to Webcast Presentation at Upcoming Investor Conference

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #bofaconference--Hologic to Webcast Presentation at Upcoming Investor Conference

Lower COVID-19 Assay Sales Weighs On Hologic's Q2 Revenue

Hologic Inc (NASDAQ: HOLX) reported Q2 FY22 sales of $1.44 billion, down 7% Y/Y, and beating the consensus Wall Street estimate for revenues of $1.29 billion. Lower sales of COVID-19 assays primarily dr...

Hologic (HOLX) Q2 Earnings Surpass Estimates, 2022 View Up

Hologic's (HOLX) second-quarter 2022 revenues decline year over year primarily due to lower COVID-19 assay sales compared to the prior year.

Chip shortage ‘impacts women's health': Hologic CEO

Steve MacMillan, the CEO of medical technology company Hologic, warned that the global semiconductor chip shortage “impacts women's health.”

Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates

Hologic (HOLX) delivered earnings and revenue surprises of 33.55% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Hologic Announces Financial Results for Second Quarter of Fiscal 2022

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #HOLX--Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the fiscal second quarter ended March 26, 2022. “In our second quart...

Is a Surprise Coming for Hologic (HOLX) This Earnings Season?

Hologic (HOLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide D...

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #ASCO--ASCO Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hologic (HOLX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Why Hologic (HOLX) is Poised to Beat Earnings Estimates Again

Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.